6 June 2023
Diaceutics PLC
("Diaceutics" or "the Company")
Purchase and Sale of Shares and PDMR Shareholdings
Diaceutics PLC, (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry announces the following Director and PDMR share dealing.
On 5 June 2023, Nick Roberts, CFO of Diaceutics, purchased 21,742 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of 91.75 pence per Ordinary Share. As a result of the purchase, Nick's shareholding is 62,576 Ordinary Shares, representing approximately 0.07% of the Company's issued share capital.
Enquiries:
|
Diaceutics PLC | |
| Peter Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer | Via Alma PR |
| | |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison | |
| Nick Harland Nick Adams Kate Hanshaw | |
| | |
| | |
| Alma PR | Tel: +44(0)20 3405 0205 |
| Caroline Forde | diaceutics@almapr.co.uk |
| Kieran Breheny Matthew Young Kinvara Verdon | |
| | |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Nick Roberts | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | CFO | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Purchase | |||||
| c. | Price(s) and volume(s) | | Share purchase: | | | | |
| | Price(s) | Volume(s) | | ||||
| 91.75p | 21,742 | | |||||
| | |||||||
| d. | Date of the transaction | 5 June 2023 | |||||
| e. | Place of the transaction | AIM Market of the London Stock Exchange | |||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
